1,125 reports of this reaction
4.0% of all LOPINAVIR AND RITONAVIR reports
#2 most reported adverse reaction
DEPRESSION is the #2 most commonly reported adverse reaction for LOPINAVIR AND RITONAVIR, manufactured by AbbVie Inc.. There are 1,125 FDA adverse event reports linking LOPINAVIR AND RITONAVIR to DEPRESSION. This represents approximately 4.0% of all 28,252 adverse event reports for this drug.
Patients taking LOPINAVIR AND RITONAVIR who experience depression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEPRESSION is moderately reported among LOPINAVIR AND RITONAVIR users, representing a notable but not dominant share of adverse events.
In addition to depression, the following adverse reactions have been reported for LOPINAVIR AND RITONAVIR:
The following drugs have also been linked to depression in FDA adverse event reports:
DEPRESSION has been reported as an adverse event in 1,125 FDA reports for LOPINAVIR AND RITONAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEPRESSION accounts for approximately 4.0% of all adverse event reports for LOPINAVIR AND RITONAVIR, making it one of the most commonly reported side effect.
If you experience depression while taking LOPINAVIR AND RITONAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.